Legal Research
Cases
SmithKline Beecham PLC v Alphapharm Pty Ltd

SmithKline Beecham PLC v Alphapharm Pty Ltd

Link copied

Case Copied 19 March 2001 17 min read

Contents

On this page

FEDERAL COURT OF AUSTRALIA
SmithKline Beecham plc v Alphapharm Pty Ltd
[2001] FCA 271
PRACTICE AND PROCEDURE – preliminary discovery – offer by respondents to make discovery of documents – whether sufficient information provided – information contains trade secrets – extent to which information should be kept confidential
Federal Court Rules O 15A, rr 6, 12
Alphapharm Pty Ltd v Eli Lilly Australia Pty Ltd (unreported, Federal Court of Australia, Lindgren J, 24 May 1996) cited
CCA Beverages (Adelaide) Ltd v Hansford (unreported, Federal Court of Australia, O’Loughlin J, 15 November 1991) applied
Warner-Lambert Co v Glaxo Laboratories Ltd [1975] RPC 354 applied
Cappuccio v Australia & New Zealand Banking Group Ltd [1999] FCA 1188applied
Harvey v Phillips (1956) 95 CLR 235 cited
Adam P Brown Male Fashions Pty Ltd v Philip Morris Inc (1981) 148 CLR 170 cited
SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED v ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND
V 935 of 2000
FINKELSTEIN J
19 MARCH 2001
MELBOURNE

IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V 935 of 2000

BETWEEN:

SMITHKLINE BEECHAM PLC, BEECHAM GROUP PLC, and SMITHKLINE BEECHAM (AUSTRALIA) PTY LIMITED
Applicants

AND:

ALPHAPHARM PTY LTD and UNIVERSITY OF QUEENSLAND
Respondents

JUDGE:

FINKELSTEIN J

DATE OF ORDER:

19 MARCH 2001

WHERE MADE:

MELBOURNE

REASONS FOR JUDGMENT

The applicants are part of a worldwide pharmaceutical group, known as the GlaxoSmithKline group. GlaxoSmithKline was established in January 2001 upon the merger of the SmithKline Beecham group and the Glaxo Wellcome group. Among the principal activities of GlaxoSmithKline are the conduct of research into, and the development and marketing of, drug therapies for use in humans.
The first applicant manufactures an antidepressant drug, the active compound of which is paroxetine hydrochloride in hemihydrate form. The drug is sold in many countries and its sales account for a significant proportion of the revenue of GlaxoSmithKline.
The second applicant is the proprietor of an Australian patent in which the invention claimed (in claim 1) is the compound crystalline paroxetine hydrochloride hemihydrate. The ‘hemihydrate’ form of the compound refers to crystalline material containing molecules of water and paroxetine hydrochloride in a fixed ratio. There are other claims, including a method of treatment for depression and processes for the preparation of the compound. It is not necessary to detail them.
The first applicant is the proprietor of an Australian patent in which the invention claimed (in claim 1) is the compound paroxetine hydrochloride anhydrate substantially free of bound propan-2-ol (an alcohol which is an organic solvent, also known as isopropanol, or isopropyl alcohol). The ‘anhydrate’ form of the compound refers to crystalline material containing paroxetine hydrochloride with negligible amounts of bound water. The compound has certain characteristics which it is not necessary to mention. Nor is it necessary to refer to the other claims, which include process and method claims, some of which are dependent on claim 1.
The first applicant is also the proprietor of an Australian patent in which the…

Grounds of appeal

[14] The appellant contends that the primary judge erred in finding that the respondent had discharged the onus of establishing the matters required under the relevant provision.

[15] It was submitted that his Honour failed to give adequate weight to the evidence of the second witness, and that the findings of fact were not reasonably open on the material before the Court.

[16] The respondent, for its part, submits that no error is disclosed, and that the conclusions reached were well within the range of outcomes available to the primary judge.

Consideration

[17] It is convenient to deal first with the question of construction, as the resolution of that issue informs the remaining grounds advanced by the appellant.

[18] For the reasons that follow, we are of the view that the appeal should be allowed in part and the matter remitted for further determination.

Keep reading for free

Create a free CaseChat account to read SmithKline Beecham PLC v Alphapharm Pty Ltd and more:

Read every judgment in full
Ask AI and get answers linked to paragraphs
See how each paragraph was cited in later cases
Download judgments as PDF or Word

Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details

Case: [2001] FCA 271
Decision Date: 19 MARCH 2001

CaseChat Overview and Summary

The case of SmithKline Beecham PLC v Alphapharm Pty Ltd concerns a dispute between the pharmaceutical companies SmithKline Beecham PLC (the applicants) and Alphapharm Pty Ltd (the respondents). SmithKline Beecham PLC, a global pharmaceutical group, holds patents for various forms of the antidepressant drug paroxetine hydrochloride. Alphapharm Pty Ltd intends to manufacture and export a generic version of the drug, PAXTINE, which may infringe these patents. The applicants sought preliminary discovery of certain documents and samples from Alphapharm to determine whether to proceed with infringement proceedings. The primary legal issue in this case was whether the applicants were entitled to the discovery of documents and samples under O 15A of the Federal Court Rules, and if so, what conditions should be imposed to protect the confidentiality of the information disclosed.

The Federal Court of Australia, presided over by Justice Finkelstein, held that the applicants were entitled to a limited discovery of documents and samples. The court reasoned that preliminary discovery under O 15A was intended to enable a party to determine whether they have a good cause of action, but it is not a substitute for general discovery. The court was satisfied that the applicants needed 50 grams of Alphapharm’s raw material (paroxetine hydrochloride) to conduct necessary tests and determine whether any of their patents had been infringed. However, the court emphasized that the discovery should be limited and subject to confidentiality protections. The court ordered that the disclosed information and test results should only be shown to specific parties, including the applicants' legal and patent advisors, and one director who could decide on the initiation of proceedings. The court also addressed the issue of costs, proposing that if infringement proceedings were brought within a specified period, the costs of the preliminary discovery application would be at the discretion of the court hearing the main action.

In summary, the court granted the applicants' request for limited preliminary discovery, ensuring that the applicants could determine whether to proceed with infringement proceedings while adequately protecting the confidential information of the respondents. The court's decision balanced the applicants' need for information to assess their potential claims against the respondents' right to protect their commercial secrets.

Orders